icad inc. (NASDAQ:ICAD) - Equities researchers at Zacks Investment Research upped their FY2017 EPS estimates for icad inc. in a research note issued to investors on Wednesday. Zacks Investment Research analyst B. Marckx now forecasts that the technology company will earn ($0.48) per share for the year, up from their prior estimate of ($0.67). Zacks Investment Research also issued estimates for icad inc.’s Q4 2017 earnings at ($0.14) EPS and FY2018 earnings at ($0.30) EPS.
icad inc. (NASDAQ:ICAD) last released its quarterly earnings data on Tuesday, August 8th. The technology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. The firm had revenue of $6.41 million during the quarter, compared to the consensus estimate of $6.41 million.
Separately, Laidlaw restated a “buy” rating and issued a $11.00 target price on shares of icad inc. in a research report on Tuesday, July 25th.
icad inc. (NASDAQ:ICAD) opened at 3.65 on Monday. icad inc. has a 1-year low of $2.82 and a 1-year high of $6.49. The company has a 50-day moving average price of $3.92 and a 200 day moving average price of $4.35. The stock’s market capitalization is $60.57 million.
Large investors have recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC increased its stake in icad inc. by 822.3% in the second quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock worth $586,000 after buying an additional 124,612 shares during the period. Vanguard Group Inc. increased its stake in icad inc. by 0.4% in the second quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock worth $1,912,000 after buying an additional 2,007 shares during the period. Finally, Argent Capital Management LLC increased its stake in icad inc. by 13.2% in the second quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock worth $2,990,000 after buying an additional 82,967 shares during the period. Hedge funds and other institutional investors own 25.16% of the company’s stock.
icad inc. Company Profile
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with MarketBeat.com's FREE daily email newsletter.
